Current standard of care guidelines recommend early initiation of terminal complement inhibitors 12 to avoid death and end-stage organ damage. Eculizumab (Soliris) 13 was approved by the North ...

Samsung Bioepis Co., Ltd. (“Samsung Bioepis”) today presented the long-term safety data of EPYSQLI™ (eculizumab; SB12), a biosimilar to Soliris 1, in paroxysmal nocturnal hemoglobinuria (PNH) at the ...

Clinical Practice Guidelines and other guidance (“Guidance”) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should ...

Objective HCV prevails in uremic haemodialysis patients. The current study aimed to achieve HCV microelimination in haemodialysis centres through a comprehensive outreach programme. Design The ERASE-C ...

Global Atypical Hemolytic Uremic Syndrome (aHUS) Treatment Market The global atypical hemolytic uremic syndrome (aHUS) treatment market is on a growth trajectory, expected to attain a value of US$ ...

Kidney Blockage: 5 Ayurvedic Herbs To Unclog Kidney Nephrons And Prevent Uremia Written by Satata Karmakar | Updated : October 24, 2024 5:51 PM IST ...

Adults and children with atypical hemolytic uremic syndrome who switched from eculizumab to ravulizumab had stable renal function and hematologic values with similar safety seen in clinical trials ...

The complement factor 5 (C5)-inhibitor eculizumab has been established as standard-of-care for the treatment of atypical hemolytic uremic syndrome (aHUS). In 2021, the long-acting C5-inhibitor ...

New Delhi: The drug major Novartis has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the Phase III b clinical ...

Research and Markets Mon, Apr 22, 2024, 5:00 AM4 min read Company Logo Dublin, April 22, 2024 (GLOBE NEWSWIRE) -- The "Uremic Pruritus - Pipeline Insight, 2024" drug pipelines has been added to ...